cohere.Chat {
	id: 59fb2e93-5b5a-4964-8903-60f234b3ffcc
	response_id: 59fb2e93-5b5a-4964-8903-60f234b3ffcc
	generation_id: f6616f26-e95d-4729-a0e4-554cd71c8fe7
	message: What company created Tebentafusp?
	text: Immunocore Ltd., located in Abingdon, UK, is the company that created Tebentafusp. Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. It is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumor cells. 

Is there anything specific you would like to know regarding Immunocore Ltd or Tebentafusp?
	conversation_id: None
	prompt: None
	chat_history: None
	preamble: None
	client: <cohere.client.Client object at 0x7f51998d2230>
	token_count: {'prompt_tokens': 1895, 'response_tokens': 108, 'total_tokens': 2003, 'billed_tokens': 116}
	meta: {'api_version': {'version': '1'}}
	is_search_required: None
	citations: [{'start': 0, 'end': 15, 'text': 'Immunocore Ltd.', 'document_ids': ['web-search_8:4', 'web-search_1:17', 'web-search_6:46']}, {'start': 28, 'end': 40, 'text': 'Abingdon, UK', 'document_ids': ['web-search_6:46']}, {'start': 100, 'end': 210, 'text': 'novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function.', 'document_ids': ['web-search_8:4']}, {'start': 221, 'end': 264, 'text': 'first molecule developed using Immunocore’s', 'document_ids': ['web-search_8:4']}, {'start': 265, 'end': 291, 'text': 'ImmTAC technology platform', 'document_ids': ['web-search_8:4', 'web-search_1:17', 'web-search_6:46']}, {'start': 292, 'end': 368, 'text': 'designed to redirect and activate T cells to recognise and kill tumor cells.', 'document_ids': ['web-search_8:4']}]
	documents: [{'id': 'web-search_8:4', 'snippet': ' Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.\n\nTebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumor cells. Tebentafusp has been granted Priority Review; Real Time Oncology Review; Breakthrough Therapy designation; Fast Track designation; and orphan drug designation by the FDA in the United States; orphan drug status in the European Union; and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma.', 'title': 'Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: ...', 'url': 'https://ir.immunocore.com/news-releases/news-release-details/immunocore-announces-publication-phase-3-data-comparing/'}, {'id': 'web-search_1:17', 'snippet': ' 9. Kimmtrak. Package insert. Immunocore Ltd; 2022. 10. Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869-5878. doi:10.1158/1078-0432.CCR-20-1247 11. Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 2019;11(7):971. doi:10.3390/cancers11070971 12. Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: why, what, how, and which. Mol Immunol. 2015;67(2, pt A):67-74. doi:10.1016/j.molimm.2015.01.024 13. Boudousquie C, Bossi G, Hurst JM, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+T cells.', 'title': 'KIMMTRAK HCP - Dosing, Admin, & Patient Support Information', 'url': 'https://www.kimmtrakhcp.com/'}, {'id': 'web-search_6:46', 'snippet': ' ‘ImmTAC’ is a registered trademark of Immunocore Ltd., Abingdon, UK.\n\nAuthor Contributions\n\nAll authors were fully responsible for all content and editorial decisions, were involved in all stages of manuscript development and approved the final version.\n\nThis research was funded by Immunocore Ltd., Abingdon, UK.\n\nConflicts of Interest\n\nBertil Damato has received consulting fees from Immunocore. Rich Carvajal has received consulting fees and research funding to institution from Immunocore. Howard Goodall and Joseph Dukes are employees of Immunocore.\n\n1. Kujala E., Makitie T., Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2003;44:4651–4659. doi: 10.1167/iovs.03-0538. [PubMed] [CrossRef] [Google Scholar]\n\n2. Lorenzo D., Piulats J.M., Ochoa M., Arias L., Gutierrez C., Catala J., Cobos E., Garcia-Bru P., Dias B., Padron-Perez N., et al.', 'title': 'Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma - PMC', 'url': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679206/'}]
	search_results: [{'search_query': {'text': 'What company created Tebentafusp?', 'generation_id': 'c5b2781f-3ee3-4efb-9e16-170e6ddfe1ec'}, 'document_ids': ['web-search_1:17', 'web-search_6:46', 'web-search_8:4'], 'connector': {'id': 'web-search'}}]
	search_queries: [{'text': 'What company created Tebentafusp?', 'generation_id': 'c5b2781f-3ee3-4efb-9e16-170e6ddfe1ec'}]
}
